-
Mashup Score: 7To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 1 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 7To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 1 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 7To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 1 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 4To RNase or Not to RNase: That Is the Question | Lupus Science and Medicine Podcast - 2 month(s) ago
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity. Read the related paper in LSM – https://doi.org/10.1136/lupus-2023-001113
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2
Dr. Anna Wolska engages in a conversation with Dr. Shivani Garg and Dr. Christie Bartels to delve into the development and implementation of HCQ-SAFE. This innovative decision-aid is designed to empower individuals living with lupus to engage in shared-decision making. The authors discuss the importance of streamlining and enhancing shared decision-making dynamics between patients and healthcare providers regarding the utilization of hydroxychloroquine, a cornerstone therapy in lupus. The tool can be accessed through the following link: http://hcqsafe.medicine.wisc.edu/ Read the article: https://doi.org/10.1136/lupus-2023-000935
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2
Dr. Anna Wolska engages in a conversation with Dr. Shivani Garg and Dr. Christie Bartels to delve into the development and implementation of HCQ-SAFE. This innovative decision-aid is designed to empower individuals living with lupus to engage in shared-decision making. The authors discuss the importance of streamlining and enhancing shared decision-making dynamics between patients and healthcare providers regarding the utilization of hydroxychloroquine, a cornerstone therapy in lupus. The tool can be accessed through the following link: http://hcqsafe.medicine.wisc.edu/ Read the article: https://doi.org/10.1136/lupus-2023-000935
Source: lupusbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
March #podcast is now available on #Lupus #Science & #Medicine This month we dive into the intricacies of #RNAse #therapy in the #management of #SystemicLupusErythematosus (#SLE) #rheumatology #autoimmunity #autoimmunedisease https://t.co/fVyvuSt9nC